Stock traders buy large volume of put options on Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) was the recipient of some unusual options trading activity on Monday. Investors bought 2,783 put options on the company. This is an increase of approximately 2,655% over the average daily volume of 101 puts.

Insider Activity at Supernus Pharmaceuticals

In related news, Vice Chairman Tami Tillotson Martin sold 5,000 shares in a trade dated Thursday, August 4. The shares were sold at an average price of $32.98, for a total value of $164,900.00. Following completion of the transaction, the vice president now owns 87,220 shares of the company, valued at approximately $2,876,515.60. The sale was disclosed in a legal filing with the SEC, accessible via this hyperlink. Separately, CEO Jack A. Khattar sold 17,302 shares in a trade dated Monday, August 15. The shares were sold at an average price of $34.03, for a total value of $588,787.06. Following completion of the transaction, the CEO now owns 759,901 shares of the company, valued at approximately $25,859,431.03. The sale was disclosed in a legal filing with the SEC, accessible via this hyperlink. Additionally, Vice President Tami Tillotson Martin sold 5,000 shares in a trade dated Thursday, August 4. The shares were sold at an average price of $32.98, for a total transaction of $164,900.00. Following completion of the transaction, the Vice President now directly owns 87,220 shares of the company, valued at approximately $2,876,515.60. The disclosure of this sale can be found here. Last quarter, insiders sold 66,733 shares of the company valued at $2,161,863. Insiders hold 8.70% of the shares of the company.

Hedge funds weigh on Supernus Pharmaceuticals

Institutional investors have recently changed their stock portfolios. First Horizon Advisors Inc. bought a new position in Supernus Pharmaceuticals stock during the second quarter worth approximately $34,000. Eagle Bay Advisors LLC increased its stake in Supernus Pharmaceuticals by 143.0% during the second quarter. Eagle Bay Advisors LLC now owns 2,663 shares of the specialty pharmaceutical company valued at $77,000 after purchasing an additional 1,567 shares during the period. CM Bidwell & Associates Ltd. increased its stake in Supernus Pharmaceuticals by 97.8% during the first quarter. CM Bidwell & Associates Ltd. now owns 2,922 shares of the specialty pharmaceutical company valued at $94,000 after purchasing an additional 1,445 shares during the period. Captrust Financial Advisors increased its stake in Supernus Pharmaceuticals by 163.3% during the first quarter. Captrust Financial Advisors now owns 2,983 shares of the specialty pharmaceutical company valued at $96,000 after purchasing an additional 1,850 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Supernus Pharmaceuticals by 28.4% during the second quarter. Nisa Investment Advisors LLC now owns 3,390 shares of the specialty pharmaceutical company valued at $98,000 after purchasing an additional 750 shares during the period. 99.81% of the shares are held by hedge funds and other institutional investors.

Price performance of Supernus Pharmaceuticals

NASDAQ:SUPN shares traded down $0.68 during Monday’s trading, hitting $32.61. 15,672 shares of the company were traded, against an average volume of 418,732. The company has a market capitalization of $1.74 billion, a PE ratio of 32.29 and a beta of 0.96. The company’s 50-day simple moving average is $33.69 and its 200-day simple moving average is $30.78. Supernus Pharmaceuticals has a 12-month low of $24.95 and a 12-month high of $36.08.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last reported results on Thursday, August 4. The specialty pharmaceutical company reported EPS of $0.14 for the quarter, missing analyst consensus estimates of $0.29 per ($0.15). The company posted revenue of $170.10 million for the quarter, compared to $164.23 million expected by analysts. Supernus Pharmaceuticals had a return on equity of 6.98% and a net margin of 9.12%. The company’s revenues increased by 20.4% compared to the same quarter last year. During the same period last year, the company posted earnings per share of $0.43. On average, sell-side analysts expect Supernus Pharmaceuticals to post EPS of 1.51 for the current fiscal year.

Wall Street analysts predict growth

Several brokerages have published reports on SUPN. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong buy” rating in a Friday, September 2 research note. Piper Sandler raised her price target on Supernus Pharmaceuticals stock to $38.00 in a Tuesday, September 6 research note.

About Supernus Pharmaceuticals

(Get an assessment)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended-release topiramate indicated for the treatment of epilepsy, as well as for the prophylaxis of migraines; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial-onset seizures in adults and children aged 6 to 17 years.

See also

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Supernus Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Supernus Pharmaceuticals was not on the list.

Although Supernus Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.